Cover Image

HARDBACK
$52.95



View/Hide Left Panel

present value of the QALYs gained would be 630. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 130. Although the number of people experiencing uncomplicated mononucleosis is far greater than those experiencing complications, slightly more than half of the QALYs lost are attributable to complicated mononucleosis due to the much lower HUI value and the longer duration.

If a vaccine program for EB V were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the health care costs saved would be $12.6 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the health care costs saved would be $2.6 million.

If a vaccine program for EBV were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the program cost would be $680 million. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the program cost would be $ 190 million.

Using committee assumptions of time and costs until licensure, the fixed cost of vaccine development has been amortized and is $11.7 million for a EBV vaccine.

If a vaccine program were implemented today and the vaccine were 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $1.1 million. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $ 1.5 million.

See Chapters 4 and 5 for details on the methods and assumptions used by the committee for the results reported.

READING LIST

Sumaya CV. Epstein-Barr Virus. In: Textbook of Pediatric Infectious Diseases. RD Feigin and JD Cherry eds. Philadelphia, PA: WB Saunder Company, 1992, pp. 1547–1557.

Schooley RT. Epstein-Barr Virus (Infectious Mononucleosis). In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1364–1376.


U.S. Bureau of the Census. Statistical Abstract of the U.S.: 1995 (115th edition). Washington, D.C. 1995.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement